36. Kanner RE, Connet JE, Murray DA, Buist S, Lee WW, Tashkin DP, Wise R; Lung Health Study. Gender difference in airway hyperresponsiveness in smokers with mild COPD. Am J Respir Crit Care Med 1994; 150:956–961. 37. de Torres JP, Casanova C, Hernandez C, Abreu J, Aguirre-Jaime A, Celli B. Gender and chronic obstructive pulmonary disease in patients attending a pulmonary clinic. Chest 2005;128:20012–20016. 38. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418–1422. 39. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608–1613. 40. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:1204–1213. 41. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114–120. 42. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297–1303. 43. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–1012.